Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept

Pharmacological Research

Volumn 43, Issue 5, 2001, Pages 429-436

  Celotti, Fabio ^a   Laufer, Stefan ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH INJURY;

EID: 0034949189     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2000.0784     Document Type: Article

References (100)

1. Inflammation
2. Mechanism of action of anti-inflammatory drugs
3. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors
4. Mechanisms of nonsteroidal anti-inflammatory drug induced gastric damage
5. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies
6. Profile and mechanisms of gastrointestinal and other side effects of nonstereoidal anti-inflammatory drugs (NSAIDs)
7. Cyclooxygenase isozymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
8. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs)
9. Specific cyclooxygenase 2 inhibitors: A new choice of nonsteroidal anti-inflammatory drug therapy
10. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
11. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
12. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
13. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
14. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
15. Differential effects of inhibitors of ciclooxygenase 1 and ciclooxygenase 2 in acute inflammation
16. COX- 1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
17. Interspecies differences in renal localization of cyclooxygenase isoforms: Implication in nonsteroidal anti-inflammatory drug-related nephrotoxicity
18. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
19. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet
20. Differential regulation of renal cyclooxygenasemRNA by dietary salt intake
21. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
22. Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa
23. Localization of cyclooxygenase-1 and cyclooxygenase-2 in adult and fetal human kidney: Implication for renal function
24. Non-steroidal anti-inflammatory drug-induced renal failure: A brief review of the role of cyclo-oxygenase isoforms
25. Renal complications of nonsteroidal anti-inflammatory drugs
26. Effect of celocoxib and naproxen on renal function in the elderly
27. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
28. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized, controlled clinical trial
29. Celecoxib: A review of its use in osteoartritis, rheumatoid arthritis and acute pain
30. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
31. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind
32. Protective effects of prostaglandins against gastric mucosal: Current knowledge and proposed mechanisms
33. Pharmacological investigation of the role of lekotrienes in the pathogenesis of experimental NSAID gastropaty
34. Treatment of aspirin-intolerant asthma with anti-leukotrienes
35. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans
36. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa
37. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection
38. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
39. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
40. Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa
41. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
42. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
43. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
44. Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases
45. Cloning of the cDNA for human 5-lipoxygenase
46. Molecular cloning and amino acid sequence of human 5-lipoxygenase
47. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
48. Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase
49. 5-Lipoxygenase binds calcium
50. Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity
51. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation
52. The role of leukotrienes in inflammation
53. Anti-inflammatory mechanisms of leukotriene modulators
54. 4 transcriptionally activates interleukin-6 expression involving NK-6B or NF-IL6
55. Leukotriene B4 induces interleukin 5 generation from human T lymphocytes
56. The role of leukotrienes in the regulation of tone and responsiveness in isolated human airways
57. Leukotriene brochocostriction induced by allergen and exercise
58. Antileukotriene therapy
59. 4 that mediates chemotaxis
60. Leukotriene B receptor: Cloning and intracellular signaling
61. Drug therapy: Treatment of asthma with drugs modifying the leukotriene pathway
62. Asthma treatment: Antileukotriene drugs
63. Leukotriene modifiers in the treatment of asthma: Look promising across the board of asthma severity
64. The antileukotrienes in the treatment of asthma
65. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed
66. Inflammatory mediators in late antigen-induced rhinitis
67. 4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis
68. 4 levels are elevated in patients with active systemic lupus erythematosus
69. 4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis
70. 4, an inflammatory mediator in gout
71. 4 by colonic mucosa in inflammatory bowel disease
72. Enhanced formation of sulfidopeptide-lekotrienes in ulcerative colitis and Crohn's disease: Inhibitionby sulphasalazine and 5-aminosalycilic acid
73. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor
74. MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis
75. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis
76. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis
77. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis
78. Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591
79. A pilot study examining the role of zileuton in atopic dermatitis
80. Use of a leukotriene inhibitor in the treatment of chronic urticaria
81. Antileukotrienes in chronic urticaria
82. The effects of leukotriene synthesis inhibitors in models of acute and chronic inflammation
83. Antiarthritic profile of BF-389, a novel anti-inflammatory agent with low ulcerogenic liability
84. Evaluation of the anti-inflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RW 63556, in a canine model of inflammation
85. Analysis of a novel anti-inflammatory agent, 1-(7-tert-butyl-2,3-dihydro3,3-dimethylbenzo[b]furan-5-yl)-4-cyclopylbutan- 1-one (PGV-20229), in plasma matrices by stable-isotope-dilution gas chromatography-mass spectrometry
86. Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities
87. Effects of supplementation with iloprost on the cardioprotection by BW755C (a dual inhibitor of cyclooxygenase and lipoxygenase enzymes) in myocardial reperfusion injury
88. Subacute and subchronic toxicology studies of CI-986, a novel anti-inflammatory compound
89. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism
90. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor
91. The in vivo anti-inflammatory effects of (E)-2,6-bis(1,1-dimethyl-ethyl)-4-[2-(5methyl-1H-pyrazol-3-yl)e thenyl] phenol (PD 127443) a novel dual inhibitor of 5-lipoxygenase and cyclooxygenase
92. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats
93. Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)- benzo(b)thiophene-2-carboxamide
94. Anti-inflammatory activity of a dual inhibitor of cyclooxygenase and lipoxygenase pathways, CBS-1108 (2-acetylthiophene-2-thiazolylhydrazone)
95. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5- yl]acetic acid in experimental animals
96. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs
97. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation Prostaglandins
98. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase
99. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]- acetic acid
100. Gastrointestinal tolerance of [2,2-dimethyl6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H-pyrroliz ine-5-yl]acetic acid in the rat